Efficacy and safety profile of roflumilast in a real-world experience
JOURNAL OF THORACIC DISEASE, vol.11, no.4, pp.1100-1105, 2019 (SCI-Expanded)
- Publication Type: Article / Article
- Volume: 11 Issue: 4
- Publication Date: 2019
- Doi Number: 10.21037/jtd.2019.04.49
- Journal Name: JOURNAL OF THORACIC DISEASE
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.1100-1105
- Keywords: Chronic obstructive pulmonary disease (COPD), roflumilast, efficacy, safety, OBSTRUCTIVE PULMONARY-DISEASE, COPD
- Akdeniz University Affiliated: Yes
Abstract
Background: Roflumilast is the only phosphodiesterase enzyme 4 inhibitor approved in the treatment of chronic obstructive pulmonary disease (COPD) patients with chronic cough and sputum and a history of exacerbations. Real-world studies about the use of roflumilast are limited. Our aim was to assess the efficacy, safety and tolerability of roflumilast in the treatment of stable COPD, in a real-world setting.